<!DOCTYPE html>
<html lang="en">

<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>AMR | Neev.bio</title>
    <link rel="stylesheet" href="style.css">
</head>

<body>

    <header>
        <h1><a href="https://www.neev.com" style="text-decoration: none; color: inherit;">Neev<span
                    style="color: #999; font-weight: normal;">.bio</span></a></h1>

        <nav>
            <a href="index.html">Home</a>
            <a href="amr.html" class="active">AMR</a>
            <a href="cancer.html">Cancer</a>
            <a href="digital_twin.html">Digital Twin</a>

            <a href="team.html">Team</a>
            <a href="#">Blog</a>
        </nav>
    </header>

    <main>
        <section>
            <p style="font-size: 1.2rem; margin-bottom: 2rem;">One of our first targets is Antimicrobial Resistance
                (AMR) - a global health challenge that threatens the effectiveness of modern medicine.</p>

            <figure style="margin: 3rem auto; text-align: center;">
                <img src="amr_deaths_map.jpg" alt="Deaths attributable to AMR every year by 2050"
                    style="max-width: 100%; width: 600px; height: auto; border-radius: 8px; box-shadow: 0 4px 12px rgba(0,0,0,0.1); margin: 0 auto;">
                <figcaption style="margin-top: 0.8rem; font-style: italic; color: #555; font-size: 0.95rem;">
                    Deaths attributable to AMR every year by 2050<br>
                    <span style="font-size: 0.85rem;">Source: <a href="https://doi.org/10.1038/nmicrobiol.2016.187"
                            target="_blank"
                            style="color: #555; text-decoration: underline;">https://doi.org/10.1038/nmicrobiol.2016.187</a></span>
                </figcaption>
            </figure>

            <p>Global Research on Antimicrobial Resistance (GRAM) project recently estimated that drug-resistant
                infections directly caused 1.14 million deaths in 2021, a figure projected to rise to 1.91 million
                annually by 2050, resulting in a cumulative loss of 39 million lives and a potential global economic
                contraction of $1.7 trillion. Antibiotic-resistant infections pose a critical global health challenge,
                and India is its epicenter compounded by the misuse of broad-spectrum antibiotics due to slow
                diagnostics. Traditional antimicrobial susceptibility testing (AST) via culture requires 1-7 days,
                forcing empirical treatment that is often inaccurate (&lt;50% appropriate). This delay and mismatch in
                therapy drive the emergence of "superbugs". &beta;-lactamases are the enzymes produced by certain
                resistant microbes that hydrolyze the &beta;-lactam ring of &beta;-lactam antibiotics like penicillins,
                cephalosporins, monobactams, and carbapenems - are among the most prevalent resistance mechanisms. They
                render our most vital antibiotics ineffective, including third-generation cephalosporins and even
                last-resort carbapenems. &beta;-lactamases are classified into four major Ambler classes (A-D),
                corresponding to broad-spectrum (penicillinases), extended-spectrum (ESBLs), AmpC cephalosporinases, and
                carbapenemases. Rapid identification of the specific &beta;-lactamase subtype present in an infection is
                crucial for personalized antibiotic therapy - for example, distinguishing a simple penicillinase
                (treatable with augmentin) from an ESBL (requiring a carbapenem) or a metallo-carbapenemase (calling for
                polymyxins or novel combos). Current phenotypic tests (like the chromogenic nitrocefin test) quickly
                indicate <em>any</em> &beta;-lactamase activity by a color change within minutes, but they do not
                differentiate enzyme subtypes or &beta;-lactam classes and are not cost-effective. Genetic tests (PCR or
                sequencing) can identify bla genes but are expensive and need lab infrastructure. There is an urgent
                need for a rapid, inexpensive (&lt;$3/test) point-of-care (POC) diagnostic that can directly detect and
                distinguish &beta;-lactamase-mediated resistance in clinical samples (blood, urine, sputum, etc.) within
                hours without culture or bulky equipment. Such a tool would enable personalized antimicrobial therapy at
                the first clinical encounter, especially in low-resource settings where over-the-counter antibiotic
                misuse is rampant.</p>

            <figure style="margin: 2rem 0; text-align: center;" class="fade-in">
                <img src="lab_research.jpg" alt="Researcher working in the lab"
                    style="max-width: 100%; width: 400px; margin: 0 auto; border-radius: 8px; box-shadow: 0 4px 12px rgba(0,0,0,0.1);">
                <figcaption style="margin-top: 0.8rem; font-style: italic; color: #555; font-size: 0.95rem;">
                </figcaption>
            </figure>



            <h3>Global AMR Mortality Trends and Projections (1990–2050)</h3>
            <p>Data derived from the Global Research on Antimicrobial Resistance (GRAM) Project</p>

            <table class="pipeline-table">
                <thead>
                    <tr>
                        <th>Metric</th>
                        <th>1990 (Historical Baseline)</th>
                        <th>2021 (Current Status)</th>
                        <th>2050 (Projected Impact)</th>
                        <th>Net Change (1990-2050)</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td class="program-name"><strong>Direct AMR Deaths</strong></td>
                        <td>~0.70 million</td>
                        <td style="color: #d32f2f;">1.14 million</td>
                        <td style="color: #d32f2f;">1.91 million</td>
                        <td style="color: #d32f2f;">+172%</td>
                    </tr>
                    <tr>
                        <td class="program-name"><strong>Associated AMR Deaths</strong></td>
                        <td>~2.50 million</td>
                        <td style="color: #d32f2f;">4.71 million</td>
                        <td style="color: #d32f2f;">8.22 million</td>
                        <td style="color: #d32f2f;">+228%</td>
                    </tr>
                    <tr>
                        <td class="program-name"><strong>Paediatric Burden (&lt;5 yrs)</strong></td>
                        <td>High</td>
                        <td style="color: #388e3c;">Reduced by 50%</td>
                        <td style="color: #388e3c;">Stable/Declining</td>
                        <td style="color: #388e3c;">-50%</td>
                    </tr>
                    <tr>
                        <td class="program-name"><strong>Geriatric Burden (70+ yrs)</strong></td>
                        <td>Low</td>
                        <td style="color: #d32f2f;">Increased by 80%</td>
                        <td style="color: #d32f2f;">Accelerating</td>
                        <td style="color: #d32f2f;">&gt; +80%</td>
                    </tr>
                </tbody>
            </table>


            <h3>Classification of beta-lactamase enzymes using the Ambler and Bush-Jacoby-Medeiros classification
                systems</h3>
            <img src="beta_lactamase_classification.png" alt="Beta-Lactamase Classification"
                style="width: 100%; height: auto; display: block; margin: 2rem auto;">
            <p style="font-size: 0.9rem; color: #666; margin-top: -1.5rem; margin-bottom: 2rem;">Carbapenemases shown in
                red. (Source - <a href="https://doi.org/10.1038/s41467-024-53192-7" target="_blank"
                    style="color: inherit; text-decoration: underline;">https://doi.org/10.1038/s41467-024-53192-7</a>)
            </p>

            <h2 style="margin-top: 4rem;">Solution</h2>
            <img src="solution_comparison.png" alt="Solution Comparison"
                style="width: 100%; max-width: 550px; height: auto; margin-top: 1rem; margin-bottom: 2rem; border-radius: 4px; display: block; margin-left: auto; margin-right: auto;">
            <h3>LFA based Rapid AMR diagnostic kit</h3>
            <p>We propose a novel chemistry-driven sensor that re-engineers &beta;-lactam antibiotics into
                Oligo-barcoded
                probes. Each probe consists of a &beta;-lactam antibiotic core (selected to be a specific enzyme's
                "bait"
                substrate) conjugated to a unique single-stranded Oligonucleotide barcode via a cleavable linker.</p>
            <p>You might be thinking why Oligonucleotide is chosen specifically over fluorophores, chromophores, or
                enzymes?</p>
            <p><strong>Because of the Multiplexing Capability</strong></p>
            <ol style="margin-bottom: 1.5rem; padding-left: 1.5rem;">
                <li style="margin-bottom: 0.5rem;">Each beta-lactamase subtype (TEM, CTX-M, NDM, OXA, etc.) gets its own
                    distinct Oligonucleotide sequence (typically 20–50 nucleotides, orthogonal so they don't
                    cross-hybridize).</li>
                <li style="margin-bottom: 0.5rem;">Impossible with simple color dyes (only 3–4 distinguishable colors
                    max)
                    or fluorescence (requires equipment and suffers spectral bleed).</li>
            </ol>



            <figure style="margin: 3rem auto; text-align: center;">
                <img src="mechanism_action.png" alt="Mechanism of Action Diagram"
                    style="max-width: 100%; width: 600px; height: auto; border-radius: 8px; box-shadow: 0 4px 12px rgba(0,0,0,0.1); margin: 0 auto;">
            </figure>

            <h3>Mechanism of Action</h3>
            <ol style="margin-bottom: 2rem; padding-left: 1.5rem;">
                <li style="margin-bottom: 0.8rem;"><strong>Enzyme Acylation (The Trigger)</strong> - The beta-lactamase
                    enzyme attacks the beta-lactam ring, creating an acyl-enzyme intermediate and breaking the cyclic
                    amide bond.</li>
                <li style="margin-bottom: 0.8rem;"><strong>Ring Opening (The Acyl-Enzyme)</strong> - The ring opening
                    restores the nitrogen's ability to donate electron density into the conjugated system, poising it to
                    initiate the cascade.</li>
                <li style="margin-bottom: 0.8rem;"><strong>Vinylogous Elimination (The Release)</strong> - The lone pair
                    pushes electron density through the conjugated system, forcing the 1,4-elimination of the C-3'
                    substituent and expelling the Oligo-carbamate linker.</li>
                <li style="margin-bottom: 0.8rem;"><strong>Spontaneous Decarboxylation</strong> - The released carbamic
                    acid (Oligo-NH-COOH) is unstable and spontaneously releases CO2, liberating the unmodified, amine-
                    terminated Oligo barcode.</li>
            </ol>
            <p style="margin-bottom: 2rem; font-style: italic;">Note - This ensures a 1:1 ratio: every single enzymatic
                hydrolysis event releases exactly one Oligo barcode, directly transducing enzymatic activity into a
                quantifiable nucleic acid signal.</p>

            <p>The principle is simple: if a target &beta;-lactamase is present in the sample, it will recognize and
                break
                down its antibiotic probe. This process releases the attached Oligo tag. Once the Oligo barcode is
                freed, it
                is detected through a colorimetric signal, allowing us to visually see which probes were cleaved.
                Essentially,
                enzymatic activity turns into an Oligo signal. This method takes advantage of how enzymes recognize
                their
                substrates and the easy multiplexing and signal boost that Oligo detection provides. By using a set of
                probes
                in a single multiplexed test (in a Lateral Flow Assay), we can identify various &beta;-lactamase classes
                or
                subtypes from one sample at the same time. Importantly, this method is phenotypic; it detects active
                enzymes
                rather than just genes. It is also quicker and more precise than broad chemical tests, combining the
                benefits
                of substrate-based sensors and Oligo barcoding. It removes the need for culture and complex instruments,
                making it suitable for point-of-care use in low- and middle-income countries.</p>

            <img src="how_it_works.jpg" alt="How It Works"
                style="margin-bottom: 2rem; max-width: 40%; height: auto; display: block; margin-left: auto; margin-right: auto;">

            <p>How it works: Each Oligo barcode is linked to a specific &beta;-lactamase type. For instance, a "CTX-M
                probe"
                may have a cefotaxime-derived core linked to Oligo barcode #A, while an "NDM probe" might use a
                carbapenem
                core linked to Oligo barcode #B, and so on. The mixture of all probes is added to the clinical sample
                after
                minimal processing. If a specific &beta;-lactamase, such as NDM-1 (a Class B carbapenemase), is present,
                it will
                break the carbapenem-Oligo probe, releasing Oligo #B into the solution. The other probes stay intact,
                meaning
                their Oligo remains tethered and does not produce a signal. After a brief incubation, the sample is
                moved to a
                detection module, like a lateral-flow strip or paper microfluidic device, which has capture zones for
                each
                Oligo barcode. The freed Oligo barcodes bind to their matching capture probes on the strip, creating a
                colored
                line, for example, using gold nanoparticles or latex bead conjugates. The appearance of a
                specific-colored line
                indicates the presence of the corresponding &beta;-lactamase enzyme in the sample. This produces a
                visual
                multi-analyte readout.</p>

            <img src="https://raw.githubusercontent.com/StackBlitz/stackblitz-images/main/amr-diagnostic-diagram.png"
                alt="AMR Architecture" onerror="this.style.display='none'">

            <div class="posts">
                <ul>
                    <li><strong>01 Conjugation:</strong> Each probe is tuned for a specific class of resistance enzyme
                        via its C-7 side chain, conjugated to a unique Oligo barcode.</li>
                    <li><strong>02 Trigger:</strong> Enzymatic hydrolysis of the antibiotic ring triggers a
                        self-immolative release, freeing the specific Oligo barcode into the sample.</li>
                    <li><strong>03 Readout:</strong> Free barcodes hybridize to spatially separated capture zones on a
                        lateral flow strip.</li>
                </ul>
            </div>

            <h3>The Probe Library</h3>
            <table class="pipeline-table">
                <thead>
                    <tr>
                        <th>Probe ID & Name</th>
                        <th>Core Chemistry</th>
                        <th>Target Logic</th>
                        <th>Description</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td class="program-name"><strong>P1</strong><br>Broad-Spectrum</td>
                        <td class="core">Ampicillin</td>
                        <td class="stage">Class A Penicillinases</td>
                        <td>Detects standard penicillin resistance (E. coli, H. influenzae).</td>
                    </tr>
                    <tr>
                        <td class="program-name"><strong>P2</strong><br>ESBL Probe</td>
                        <td class="core">Cefotaxime</td>
                        <td class="stage">Class A ESBLs</td>
                        <td>Identifies resistance to 3rd-gen cephalosporins (CTX-M).</td>
                    </tr>
                    <tr>
                        <td class="program-name"><strong>P3</strong><br>AmpC Probe</td>
                        <td class="core">Cefoxitin</td>
                        <td class="stage">Class C Cephalosporinases</td>
                        <td>Differentiates AmpC-mediated resistance from ESBLs.</td>
                    </tr>
                    <tr>
                        <td class="program-name"><strong>P4</strong><br>Carbapenemase</td>
                        <td class="core">Imipenem</td>
                        <td class="stage">Class A, B, D Carbapenemases</td>
                        <td>Flags critical resistance to carbapenems.</td>
                    </tr>
                </tbody>
            </table>

            <h3 style="text-align: center; font-size: 1.4rem; font-weight: 500; margin-top: 3rem; margin-bottom: 2rem;">
                The released Oligo barcodes are detected using a multiplexed LFA built on "Sandwich Hybridization"
                model.
            </h3>
            <p style="text-align: center; font-size: 0.9rem; margin-top: -1.5rem; color: #666; font-style: italic;">
                (*Oligo refers to Oligonucleotides)</p>

            <div
                style="display: flex; justify-content: space-between; align-items: flex-start; gap: 1.5rem; margin-top: 2rem; margin-bottom: 2rem;">
                <div style="width: 32%;">
                    <img src="reporter_oligo.jpg" alt="Reporter Oligo"
                        style="width: 100%; height: auto; margin-bottom: 1rem;">
                    <h4 style="font-size: 1rem; margin-bottom: 0.5rem; font-weight: bold;">1. Rehydration &
                        Hybridization</h4>
                    <p style="font-size: 0.9rem; margin-bottom: 0; text-align: left;">The sample containing the released
                        barcodes flows over a conjugate pad, rehydrating gold nanoparticles (AuNPs). Each AuNP is coated
                        with a "Reporter Oligo" sequence that binds to one half of a specific barcode.</p>
                </div>
                <div style="width: 32%;">
                    <img src="test_line.jpg" alt="Test Line" style="width: 100%; height: auto; margin-bottom: 1rem;">
                    <h4 style="font-size: 1rem; margin-bottom: 0.5rem; font-weight: bold;">2. Migration & Capture</h4>
                    <p style="font-size: 0.9rem; margin-bottom: 0; text-align: left;">The AuNP-barcode complex migrates
                        along a nitrocellulose membrane to a "Test Line". This line is striped with "Capture Oligo"
                        complementary to the other half of the barcode.</p>
                </div>
                <div style="width: 32%;">
                    <img src="visible_signal.jpg" alt="Visible Signal"
                        style="width: 100%; height: auto; margin-bottom: 1rem;">
                    <h4 style="font-size: 1rem; margin-bottom: 0.5rem; font-weight: bold;">3. Signal Formation</h4>
                    <p style="font-size: 0.9rem; margin-bottom: 0; text-align: left;">The complex is immobilized at the
                        test line. This concentration of AuNPs produces a distinct red line visible to the naked eye,
                        confirming the presence of the specific resistance enzyme. Each resistance profile (e.g. ESBL,
                        Carbapenemase) corresponds to a spatially distinct line on the strip.</p>
                </div>
            </div>
            </div>

            <br>

            <img src="lfa_diagram.png" alt="LFA Diagram - Sandwich Hybridization"
                style="width: 100%; max-width: 900px; height: auto; display: block; margin: 0 auto 3rem auto;">

            <div style="margin-top: 4rem; margin-bottom: 3rem;">
                <h2>Seamless Implementation</h2>
                <p>Needing no complex machinery, just human-centric engineering.</p>
                <ol style="padding-left: 1.5rem; margin-bottom: 2rem; line-height: 1.8;">
                    <li><strong>Collect:</strong> Small volume of Blood or Sputum.</li>
                    <li><strong>Lysis:</strong> Mix with reagent to release bacterial enzymes.</li>
                    <li><strong>Incubate:</strong> Wait for probe cleavage & activation.</li>
                    <li><strong>Read:</strong> Visual pattern readout on lateral flow.</li>
                </ol>
            </div>

            <div style="display: flex; gap: 2rem; align-items: flex-start; margin-bottom: 3rem;">
                <div style="flex: 0.8;">
                    <img src="lfa_annotated_strip.png" alt="Annotated Test Strip"
                        style="width: 100%; height: auto; border-radius: 4px;">
                </div>
                <div style="flex: 1.2;">
                    <img src="lfa_mdr_comparison.jpg" alt="MDR Comparison"
                        style="width: 100%; height: auto; border-radius: 4px;">
                </div>
                <div style="flex: 2;">
                    <table class="pipeline-table" style="width: 100%; font-size: 0.9rem;">
                        <thead>
                            <tr>
                                <th>Antibiotic</th>
                                <th>Result</th>
                                <th>Interpretation</th>
                                <th>Clinical Action</th>
                            </tr>
                        </thead>
                        <tbody>
                            <tr>
                                <td>Ampicillin</td>
                                <td>Positive (Strong)</td>
                                <td style="color: #d32f2f; font-weight: bold;">Resistant</td>
                                <td>Do not prescribe</td>
                            </tr>
                            <tr>
                                <td>Cefotaxime</td>
                                <td>Positive (Weak)</td>
                                <td style="color: #ed6c02; font-weight: bold;">Intermediate</td>
                                <td>Risk of failure</td>
                            </tr>
                            <tr>
                                <td>Imipenem</td>
                                <td>Negative</td>
                                <td style="color: #2e7d32; font-weight: bold;">Susceptible</td>
                                <td>Recommended therapy</td>
                            </tr>
                        </tbody>
                    </table>
                </div>
            </div>

            </div>



            <p style="margin-top: 2rem; margin-bottom: 2rem; font-size: 1rem; line-height: 1.6;">
                I have worked closely with leading infectious disease specialists, research scientists, and clinicians
                to
                test our approach. The feedback has been clear: experts agree that the current delay in diagnostics is
                not acceptable and that our solution tackles the exact problem clinicians encounter every day. They have
                confirmed that this technology could significantly change antibiotic use, shifting the standard of care
                from guesswork to precise medicine. My team and I believe that this solution has a real chance of not
                only solving the diagnostic bottleneck in India, but setting a new standard for the world. We have the
                blueprint and the clinical backing; we just need some early support to allow us to prove it.
            </p>

            <figure style="margin: 3rem auto; text-align: center;">
                <img src="amr_process.png" alt="Diagnostic Process Overview"
                    style="max-width: 100%; width: 800px; height: auto; border-radius: 8px; box-shadow: 0 4px 12px rgba(0,0,0,0.1); margin: 0 auto;">
            </figure>

            <p style="font-weight: bold; margin-top: 3rem; font-size: 1.2rem;">The earlier you know, the better your
                chances.</p>

            <div
                style="margin-top: 4rem; text-align: center; border-top: 1px solid var(--border-color); padding-top: 2rem;">

                <div style="display: flex; justify-content: center; align-items: center; gap: 3rem; flex-wrap: wrap;">
                    <img src="icmr_logo.jpg" alt="ICMR"
                        style="height: 60px; width: auto; filter: grayscale(100%); opacity: 0.8; transition: all 0.3s ease;">
                    <img src="scb_logo.png" alt="SCB Medical College"
                        style="height: 60px; width: auto; filter: grayscale(100%); opacity: 0.8; transition: all 0.3s ease;">
                    <img src="ravenshaw_logo.png" alt="Ravenshaw University"
                        style="height: 70px; width: auto; filter: grayscale(100%); opacity: 0.8; transition: all 0.3s ease;">
                    <img src="bric_ils_logo.jpg" alt="BRIC-ILS"
                        style="height: 60px; width: auto; filter: grayscale(100%); opacity: 0.8; transition: all 0.3s ease;">
                </div>
            </div>
        </section>
    </main>

    <footer>
        <p>Neev.bio &copy; 2026</p>
        <p>
            <a href="mailto:hello.neev.bio@gmail.com">hello.neev.bio@gmail.com</a>
            <a href="#">Twitter</a>
        </p>
        <p style="margin-top: 1rem; font-size: 0.8rem; color: #999;">Built at the intersection of Bio, Engineering &
            Code</p>
    </footer>

    <script src="script.js"></script>
</body>

</html>